Cardica to Announce Fiscal 2008 Fourth Quarter and Year End Financial Results on Tuesday, Augu...( REDWOOD CITY Calif. July 29 /- Ca...),Health
Navigation Links
Cardica to Announce Fiscal 2008 Fourth Quarter and Year End Financial Results on Tuesday, August 5, 2008
Date:7/29/2008
REDWOOD CITY, Calif., July 29 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today announced that it will release financial results for its fiscal fourth quarter and year ended June 30, 2008 on Tuesday, August 5, 2008 after the markets close, and the company's management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
Conference Call Details
To access the live conference call on August 5, 2008 at 4:30 p.m. Eastern Time via phone, please dial 800-659-2032 in the United States and Canada or +1-617-614-2712 internationally. The conference ID is 76383319. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through August 12, 2008 and may be accessed by dialing 888-286-8010 from the United States and Canada or +1-617-801-6888 internationally. The replay passcode is 84453290.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of Cardica's website at http://www.cardica.com. Please connect to the website at least 15 minutes prior to the call to allow for any necessary software downloads.
The webcast is also being distributed through the Thomson StreetEvents
Network. Individual investors can listen to the call at
http://www.earnings.com, Thomson's individual investor portal, powered by
StreetEvents. Institutional investors can access the call via Thomson
StreetEvents (http://www.streetevents.com), a passw
'/>"/>
| SOURCE Cardica, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Cardica Names Frederick Bauer Vice President of Operations
2. Renowned Leader and Educator in Robotic Cardiac Bypass Surgery Leverages Cardicas C-Port(R) Flex-A(R) Anastomosis System in His Practice and to Educate Cardiothoracic Surgeons
3. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
4. Cardica to Announce Fiscal 2008 Third Quarter Financial Results on Tuesday, April 29, 2008
5. Cardicas C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study
6. Cardicas C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University
7. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
8. Cardica Announces Exercise of Over-Allotment Option
9. Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
10. Cardica Announces Pricing of $34.7 Million Public Offering of Common Stock
11. Cardica Announces Proposed Public Offering of Common Stock
Post Your Comments:
(Date:11/8/2009)...the battle is won," said Dr. Charmaine Yoest. ,...n a vote of 240-194, the Stupak-Ellsworth-Pitts-Ka...it abortion mandates and funding in HR 3962 passed...fe Action President and CEO Dr. Charmaine Yoest sa...r the pro-life Americans across this country who h...
(Date:11/8/2009)...H.R. 3961 to Secure the Stability of Medicare ,...ement Attributable to: J. James Rohack, M.D., Pres... http://www.newscom.com/cgi-bin/prnh/20081209/AMA...ouse health reform bill, which will help improve t...alls for swift passage of H.R. 3961 to secure the ...
(Date:11/8/2009)...of Health Care Reform Bill ,, Critical legisl...for all Americans ,, BALTIMORE, Nov. 7 /PRNews...States House of Representatives passed critical he... Medicare for seniors and end discrimination by in...s out of affordable health coverage. ,, The Aff...
(Date:11/7/2009)...-USNewswire/ -- The American Medical Association (...r Citizenship and Community Service to Manus C. Kr...e award recognizes physicians who have gone above ... an outstanding public service contribution to the...oday during the opening session of the 2009 Interi...
(Date:11/7/2009)...USNewswire/ -- Members of the AMA are trying a las...on rescinding the AMA,s support of HR 3962. ,,...nsible to their PATIENTS, not the leadership of th...r the Association of American Physicians and Surge...medical groups. ,, "If the AMA leadership igno...
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2[1] Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People[0] AMA Hails House Passage of Health Reform Bill (H.R. 3962)[0] AARP Maryland Key Vote News Alert[1] AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members[0] AMA Has Chance to Rescind Support of HR 3962; AMA Shout-Out from Public Urges Doctors to Answer to PATIENTS Not AMA Leadership
...Dec. 17 OmniComm Systems,Inc. (OTC: OMCM.OB), a l...solutions for clinical trials, today announced tha... financing. OmniComm will use the capital to fina...ers of the Company,s executive,management team inc...
...leader selects software formultistage inventorypla...17 SmartOps Corporation, the leading provider of ...ns, announced that its Enterprise Inventory Optimi... companies optimize their use of working capital w...
...Microencapsulation isn,t a new technology, but it,...nclude the scratch-and-sniff perfume ads in magazi...rhaps mostly for an older generation) carbonless c...roencapsulation technology in a novel self-warming...
...ns of bacteria make their home in the vertebrate g...duties for their host, othersthe pathogensare unwe...typhimurium is one such pathogenic bacterium. It ...for most cases of food-borne illness. Yixin Shi, a...
... and low-cost method of preventing lung disease a...ng practiced widely enough in South-East Asian hos...nvolving the University of Adelaide, Australia. , ... the practice of using antenatal corticosteroids p...
...his week marks the launch of Health,Sciences Onlin...e can search,for and find more than 50,000 courses...d, high-quality, current, cost-free, and ad-free h...ners and public health providers,enabling their tr...
Other Medicine News:Health News:OmniComm Systems, Inc. Raises $5.1 Million in Convertible Debt Financing 2Health News:OmniComm Systems, Inc. Raises $5.1 Million in Convertible Debt Financing 3Health News:SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth Pharmaceuticals 2Health News:Sandia's microencapsulation project gives local entrepreneur warm glow 2Health News:Sandia's microencapsulation project gives local entrepreneur warm glow 3Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 2Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 3Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 4Health News:More can be done to prevent lung disease in Southeast-Asian babies 2Health News:Visionary Undertaking for Global E-Health Education 2Health News:Visionary Undertaking for Global E-Health Education 3Health News:Visionary Undertaking for Global E-Health Education 4OmniComm Systems, Inc. Raises $5.1 Million in Convertible Debt FinancingSmartOps Enterprise Inventory Optimization Software Licensed by Wyeth PharmaceuticalsSandia's microencapsulation project gives local entrepreneur warm glowGut instinct: Salmonella bacteria's molecular tactics to cause illnessMore can be done to prevent lung disease in Southeast-Asian babiesVisionary Undertaking for Global E-Health Education
(Date:11/6/2009).... 6 SCOLR Pharma, Inc. (...the three and nine months ended September 30, 2009...ent and CEO, said, "We continue to advance discuss...rmulation. Several potential partners have committ...ternal resources as they evaluate the potential co...
(Date:11/6/2009)...PRNewswire/ -- Trius Therapeutics, Inc. announced ...n Form S-1 with the U.S. Securities and Exchange C...lic offering of shares of its common stock. All sh...g will be offered by the Company. ,, Credit Sui...nning manager, Piper Jaffray & Co. is acting a...
(Date:11/6/2009)...Newswire-FirstCall/ -- Caraco Pharmaceutical Labor...rolac tromethamine ophthalmic solution, 0.5% follo...ministration (FDA) for Sun Pharma,s Abbreviated Ne... ophthalmic solution on the first day following pa...rapeutically equivalent to Acular® Ophthalmic...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Siblings target of intervention program 50533 1Both good bad movie characters who smoke influence teens to do the same 50531 1Both good bad movie characters who smoke influence teens to do the same 50531 2Colorectal cancer 9090 1...OUTH SAN FRANCISCO, July 9 Cerimon Pharmaceutical...I proof-of-concept study of,Simulect(R) (basilixim...chronic and potentially sight-threatening inflamma...acebo-controlled study will evaluate the,safety an...6 patients.,During the study, patients will underg...
...AN DIEGO, July 9 Arena Pharmaceuticals, Inc.,(Nas... a multiple-ascending,dose Phase 1b clinical trial...acokinetics and pharmacodynamics. APD791 is Arena,...ed for the treatment of arterial,thrombosis and ot... randomized, double-blind, placebo-controlled,mult...
Other Medicine Technology:Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 5Plus Cylinders only Trial Lens Set
Magnetic LAnthony 15 desaturated Kit (4 lbs)
Opti-Free Express No Rub
Grafton Trial Frame
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |